On November 27, 2023 Oncoteq AG (Oncoteq), a clinical stage biotech company specializing in novel and innovative cancer treatments, is expanding its development pipeline by in-licensing the potential best-in-class antibody drug conjugate (ADC) TEQ102 from biotech company Tubulis for the treatment of patients with CD30-positive lymphomas, including, but not limited to, T-cell and Hodgkin’s lymphomas (Press release, Tubulis, NOV 27, 2023, View Source [SID1234651625]). Patients with these types of lymphomas and whose disease recur are faced with limited treatment options that have relatively poor long-term outcomes.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TEQ102 was designed and developed by Tubulis, a biotechnology company based in Munich, Germany. The ADC utilizes the documented efficacy of CD30-directed anti-tumor treatment while optimizing tolerability through the superior improved linker technology. Drug safety and tolerability enhanced with such optimization may enable longer treatment and/or higher dosages of the ADC which is expected to result in greater efficacy as compared with the limited number of treatment courses and dosages that can currently be delivered with known anti-CD30 ADCs. TEQ102 is therefore designed to improve treatment outcomes and quality of life of lymphoma patients.
TEQ102 targets a market currently valued at USD ~1.5bn but expected to grow towards USD 3bn in the coming years, representing a significant commercial opportunity.
Mads Dalsgaard, Chief Executive Officer of Oncoteq, comments: "We are excited to again execute on our strategy to build a pipeline of promising future cancer treatments and to secure rights to what can be a significant improvement in treatment options for patients with CD30-positive lymphomas.
TEQ102 has the potential to be superior to current therapies and addresses a marked unmet medical need. We are looking forward to quickly advancing the development of the compound towards clinical testing."
Dominik Schumacher, Chief Executive Officer, and co-founder of Tubulis, adds: "This licensing agreement with Oncoteq further validates our differentiated ADC development platform and technology, demonstrating we can deliver a clinical stage-ready and therapeutically relevant drug candidate. The Oncoteq team brings the right expertise and knowledge to advance TEQ102 through clinical development to deliver the highest benefits for patients, while we continue to develop and expand our growing, innovative pipeline of ADCs uniquely matched for patients with solid tumors."
Under the terms of the agreement, Oncoteq obtains a worldwide exclusive license for the development and commercialization of TEQ102. Tubulis will be entitled to an upfront payment as well as development-based milestone payments and royalties on future sales.